Truist analyst Danielle Brill raised the firm’s price target on BridgeBio (BBIO) to $95 from $86 and keeps a Buy rating on the shares. The company had pre-announced Q4 Attruby sales of $146M, up 35% from Q3, in January, which solidly beat estimates for the quarter, and the performance was importantly driven by an acceleration in the pace of new patient adds, which appears to be continuing, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $98 from $96 at Morgan Stanley
- BridgeBio price target raised to $125 from $100 at Evercore ISI
- BridgeBio price target lowered to $81 from $83 at Oppenheimer
- BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside
- BridgeBio: Robust Attruby Launch and Late-Stage Pipeline Support Buy Rating and Path to Sustainable Cash Generation